Articles related to STIMULANTS
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.
Psychiatry November 7th 2023
Understanding the Stimulant Shortage
The stimulant crisis is affecting ADHD treatment across the board; Dr. Greg Mattingly offers crucial insights into navigating this challenging landscape. Learn about alternative treatment options to better serve your patients.
Psychiatry September 12th 2023
DEA, FDA Address Prescription Stimulant Shortage in Joint Letter
The DEA and FDA are addressing the current prescription stimulant shortage, emphasizing both the importance of patient access and the need for responsible prescribing. Stay informed on the latest updates and consider alternative treatments where appropriate.
Psychiatry August 8th 2023